News
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
9mon
India Today on MSNUS approves first nasal spray flu vaccine that can be self-administeredFluMist is the first vaccine to prevent influenza, more commonly known as the flu, that does not need to be administered by a ...
Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...
The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
20h
Bizcommunity on MSNSouth Africa issues first permit for avian influenza vaccinationThe Department of Agriculture has issued its first-ever permit to vaccinate poultry against highly pathogenic avian influenza ...
Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results